Trial · NCT04394624
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Any TEAE | 31 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Any treatment-emergent SAE | 7 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Hematology | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Anemia | 19 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Hematology | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | White blood cell decreased | 8 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Hematology | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Neutrophil count decreased | 8 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Hematology | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Lymphocyte count decreased | 11 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Hematology | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Eosinophilia | 12 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Hematology | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Platelet count decreased | 21 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Hematology | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | International normalized ratio increased | 2 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Hematology | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Activated partial thromboplastin time prolonged | 11 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Metabolism | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Hypoglycemia | 1 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Metabolism | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Hypoalbuminemia | 16 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Metabolism | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Total protein: <Lower limit of normal | 3 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Metabolism | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Total protein: >Upper limit of normal | 4 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Electrolytes | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Hyponatremia | 15 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Electrolytes | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Hypernatremia | 2 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Electrolytes | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Hypokalemia | 7 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Electrolytes | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Hyperkalemia | 9 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Electrolytes | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Hypocalcemia | 6 | Participants | |
| Number of Participants With Potentially Clinically Significant Abnormalities: Electrolytes | Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab | Hypercalcemia | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04394624/results